SCHEMBL27244

SCHEMBL27244

COC1([O])CCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512636 0.71
SCHEMBL6566354 0.70
SCHEMBL10382153 0.68
SCHEMBL28963232 0.67
SCHEMBL5609556 0.67
SCHEMBL2283816 0.67
SCHEMBL2878964 0.67
SCHEMBL9935103 0.66
SCHEMBL14996909 0.66
SCHEMBL30732609 0.66 NPSR1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210071181-A1 PHARMACEUTICAL COMPOSITION ROCHE INNOVATION CT COPENHAGEN AS (DK) 2021-03-11 US disclosed
EP-3372684-B1 SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER SIRNA THERAPEUTICS INC (US) 2020-10-07 EP disclosed
US-10584335-B2 Single-stranded RNAi agents containing an internal, non-nucleic acid spacer SIRNA THERAPEUTICS, INC. (US) 2020-03-10 US disclosed
EP-3502255-A1 PHARMACEUTICAL COMPOSITION Roche Innovation Center Copenhagen A/S (DK) 2019-06-26 EP disclosed
US-20190071672-A1 Pharmaceutical Composition ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2019-03-07 US disclosed
EP-3431602-A1 PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES Roche Innovation Center Copenhagen A/S (DK) 2019-01-23 EP disclosed
EP-2666859-B1 PHARMACEUTICAL COMPOSITION COMPRISING ANTI-MIRNA ANTISENSE OLIGONUCLEOTIDES ROCHE INNOVATION CT COPENHAGEN AS (DK) 2019-01-02 EP disclosed
EP-3372684-A1 SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER Sirna Therapeutics, Inc. (US) 2018-09-12 EP disclosed
US-20180195062-A1 Pharmaceutical Composition SANTARIS PHARMA A/S (DK) 2018-07-12 US disclosed
US-20180112216-A1 SEGMENTED MICRO RNA MIMETICS BANK OF AMERICA, N.A. 2018-04-26 US disclosed
WO-2004069990-A2 OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION SANTARIS PHARMA A/S (DK) 2004-08-19 WO disclosed
US-20040106070-A1 Method to enhance resolution of a chemically amplified photoresist INTERNATIONAL BUSINESS MACHINES CORPORATION 2004-06-03 US disclosed
US-20040096848-A1 Oligomeric compounds for the modulation HIF-1alpha expression ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2004-05-20 US disclosed
WO-2003085110-A2 OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION SANTARIS PHARMA A/S (DK) 2003-10-16 WO disclosed
US-6534243-B1 A coating containing a cleaving compound to trim resist features; permitting a deprotection region to form within an inner portion of the patterned resist; removing coating and deprotection region to provide a second patterned feature ADVANCED MICRO DEVICES, INC. 2003-03-18 US disclosed
US-6492075-B1 COATING WITH CLEAVING COMPOUND TO CONTROLLABLY DECREASE SIZE OF DEVELOPED RESIST ADVANCED MICRO DEVICES, INC. 2002-12-10 US disclosed
US-6274289-B1 Chemical resist thickness reduction process ADVANCED MICRO DEVICES, INC. 2001-08-14 US disclosed
US-5880169-A HAVING HIGH RESOLUTION FOR FINE PATTERNING SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-03-09 US disclosed
US-5847218-A Sulfonium salts and chemically amplified positive resist compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1998-12-08 US disclosed
US-5824824-A AROMATIC SULFONATE ANIONS AND DISSOLUTION CONTRAST IN EXPOSED AND NONEXPOSED AREAS, POSITIVE RESISTS SHIN-ETSU CHEMICAL CO., LTD. (JP) 1998-10-20 US disclosed